QuantLogix ← ABT scorecard
📅 ABT Earnings Preview
Abbott Laboratories
Next report (est.)
01/04/2027
Countdown
114 days
EPS growth YoY
-30.3%
Revenue growth YoY
+21.6%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
07/28/2026 ±2.3% +2.7% under-priced
04/29/2026 ±2.2% -2.7% under-priced
07/30/2025 ±1.6% +0.4% over-priced
04/30/2025 ±2.2% +0.2% over-priced
10/31/2024 ±1.6% -0.9% over-priced
07/31/2024 ±3.3% +0.6% over-priced
05/02/2024 ±1.3% -0.3% over-priced
11/01/2023 ±2.3% +0.5% over-priced
Across these reports, options implied an average ±2.1% move vs an actual average of 1.0% — the stock stayed inside the implied band 75% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $0.53 $12.6B $928M
Q1 FY2026 $0.61 $11.2B $1.1B
Q4 FY2025 — $0 $0
Q2 FY2025 $1.01 $11.1B $1.8B
Analyst posture
Buy / Strong Buy
25
Hold
8
Sell
0
Stable: +2 net change 30d
Live 5-factor engine read: Underweight · 32/100 Full scorecard →
Get alerted before every ABT report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on ABT before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Abbott Laboratories (ABT) reports in 114 days, with the next report estimated for 01/04/2027. Across the last 8 reports, options priced an average ±2.1% earnings move while the stock actually moved 1.0% on average — the market has systematically over-priced ABT's earnings risk. Fundamentals into the print: EPS down 30.3% year-over-year, revenue up 21.6%. QuantLogix's live 5-factor engine currently reads ABT as a underweight at 32/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →